Biocad and Roche main suppliers of anticancer drugs within Russian state program in 2019

Russian drugmaker Biocad and Swiss pharma giant Roche (ROG: SIX) became the main suppliers of anticancer drugs as part of the Russian “Healthcare” national state project in 2019, according to recent statements made by some senior officials of the Russian Ministry of Health and some local media, reports The Pharma Letter’s local correspondent.

According to their data, during the period of January-November 2019 both Biocad and Roche sold drugs totalling 12.5 billion roubles ($204 million) and 10.7 billion roubles ($172 million), respectively.

Such high results achieved by the companies could be explained by the increase of the overall volume funding of the entire program by the state, which last year reached almost 70 billion roubles, compared to 28.9 billion roubles a year earlier.